Chemotherapy for Retinoblastoma
For bilateral or advanced intraocular retinoblastoma, use vincristine and carboplatin (VC) for early-stage disease (International Classification Groups A-B), and add etoposide to create the VEC regimen (vincristine, etoposide, carboplatin) for advanced intraocular disease (Groups C-D). 1, 2
Treatment Selection by Disease Stage
Early Intraocular Disease (Groups A-B)
- Two-drug combination of vincristine and carboplatin is the standard regimen for Reese-Ellsworth groups I-III and International Classification Groups A-B 1
- This approach minimizes toxicity while maintaining efficacy in less advanced tumors 2
Advanced Intraocular Disease (Groups C-D)
- VEC regimen (vincristine, etoposide, carboplatin) is required for Reese-Ellsworth groups IV-V and International Classification Groups C-D 1, 2
- VEC demonstrated superior event-free eye survival (72.3% at 2 years) compared to cyclophosphamide-containing regimens (50.4% at 2 years), despite omitting cyclophosphamide 3
- The higher carboplatin doses in VEC appear to drive better outcomes without adding cyclophosphamide-related toxicity 3
Alternative Topotecan-Based Regimen for Advanced Disease
- For highly advanced bilateral disease, consider topotecan-based therapy: two courses of topotecan plus vincristine, followed by three alternating cycles of carboplatin/vincristine (two courses) and topotecan/vincristine (one course) 4
- This regimen achieved 69.2% event-free survival at 10 years and 77.5% ocular survival for Reese-Ellsworth group IV-V eyes 4
- Vision outcomes were excellent: 76% of patients achieved 20/40 or better vision in at least one eye 4
- Toxicities included manageable thrombocytopenia (15% of courses) and febrile neutropenia (10% of courses), with grade 3 diarrhea in one-third of patients 4
Critical Adjunctive Therapies
Focal Consolidation (Essential Component)
- All chemotherapy must be combined with aggressive focal therapies applied during examinations under anesthesia every 4-6 weeks 1, 2
- Cryotherapy for small anterior tumors 1
- Thermotherapy and laser photocoagulation for small posterior tumors 1
- Brachytherapy (plaque radiotherapy) for larger tumors 1, 5
Periocular Carboplatin
- Add subconjunctival carboplatin for vitreous seeds with poor response to systemic chemotherapy 1, 6
- Periocular chemotherapy serves as adjunct treatment in Group D and E retinoblastoma with persistent or recurrent vitreous seeds 6
Route-Specific Chemotherapy Options
- Intra-arterial chemotherapy (IAC) is reserved for Group C or D disease and selected Group E tumors 6, 7
- Intravitreal chemotherapy is used only for persistent or recurrent vitreous seeds after other treatments have failed 6, 7
Unilateral vs. Bilateral Disease Considerations
- Bilateral tumors have significantly better success rates with chemoreduction (54%) compared to unilateral tumors (19%) when attempting globe salvage 5
- For unilateral advanced disease (Reese-Ellsworth IV-V), success rates with chemoreduction are poor (0%), making primary enucleation often more appropriate 5
- Intravenous chemotherapy is the preferred first-line approach for bilateral cases 6
Critical Genetic Testing Requirement
- Immediate germline RB1 testing is mandatory before considering any radiotherapy, as approximately 45% of cases are hereditary 8
- Children with germline RB1 mutations who receive radiotherapy face markedly increased lifetime risk of secondary malignancies, especially sarcomas and melanomas 8
- Germline mutation status fundamentally alters the risk-benefit calculus and must guide treatment decisions 8
Common Pitfalls to Avoid
- Do not delay genetic testing—knowing RB1 status is required for proper counseling about radiation-associated risks 8
- Do not use cyclophosphamide-containing regimens (CyVEC) when VEC achieves superior event-free eye survival with less toxicity 3
- Do not attempt chemoreduction for unilateral Reese-Ellsworth IV-V disease given 0% success rates; proceed directly to enucleation 5
- Do not omit focal consolidation therapies—chemotherapy alone is insufficient; most failures occur from vitreous seed progression 1
- Age older than 12 months and less advanced International Classification grouping (A/B/C) are associated with better event-free eye survival 3